N/A N=20 Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)
Solid Neoplasms With NTRK Fusions
Primary: Duration of Response (DoR) — 24.5 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=27 IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
Prostate Cancer
Primary: Percentage Change of Phospho-IGF-1R Positive Tumour Cells Following Treatment With Xentuzumab — -8.28 Percentage change Phospho-IGF-1R+ cells
Phase 2 N=24 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Biochemically Recurrent Prostate Cancer
Primary: Percent Change in Serum Testosterone — 53.46 percentage (%)
N/A N=101 A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
Prostate Cancer
Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives
Phase 2 N=13 Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Prostate Cancer
Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants
N/A N=2,384 Modeling Clinical Failure in Prostate Cancer Patients Based on a Two-stage Statistical Model
Prostate Cancer
Primary: Number of Participants With Clinical Failure After Initiation of Radiotherapy — 315 Participants
Phase 1 N=41 A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Prostate Specific Antigens · Prostate Neoplasms
Primary: Number of Participants With a Positive Immune Response Following Vaccination Determined by Interferon (IFN) Gamma Enzyme-linked Immunosorbent Spot (ELISpot) — 12; 10…
Phase 2 N=27 Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Prostate Cancer · Prostatic Neoplasms · Neoplasms, Prostate
Primary: Changes From Baseline to After Surgery of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Infiltrates — 132.2; 153.7; 105.1; 140.5…
Early Phase 1 N=116 18F-DCFBC PET/CT in Prostate Cancer
Prostatic Neoplasms · Prostate Cancer
Primary: Number of Participants With Local Recurrence, Lymph Node Metastases or Distant Metastatic Sites Detected by…
Phase 2 N=31 Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]
Healthy
Primary: Prostate Tissue DHT and Testosterone Levels After 28 Days of Treatment With Dihydrotestosterone [DHT] Gel Versus Placebo Gel. — 2.8; 3.1; 0.6; 0.4 ng/g
Phase 1 N=17 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Prostate Cancer · Prostatic Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)
Phase 2 N=30 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Blasts 10 Percent or More of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia-2 · High Grade Malignant Neoplasm
Primary: Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant — 9; 21 Participants
Phase 2 N=77 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Peripheral T Cell Lymphoma · PTCL · Extranodal NK/T-cell Lymphoma
Primary: Overall Response Rate (ORR) — 31.8; 20.5; 45.5 Percentage of participants
Phase 2 N=97 Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
Prostatic Hyperplasia
Primary: Rate of Progression to Prostate Cancer (PCa) — 4; 6 participants
Phase 2 N=93 FACBC PET/CT for Recurrent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With True Positive Scans Within the Prostate Bed — 55; 41 participants